Novo Nordisk Reports 28% Weight Loss With Higher-Dose Wegovy
Bagsværd, Denmark, May 12, 2026 Novo Nordisk presented new analyses from its pivotal STEP UP clinical trial at the...
Semaglutide
Advertisement
Apotex Gains Canada Approval for Generic Ozempic
Toronto, Canada | May 1, 2026 Apotex has received Health Canada approval for Apo-Semaglutide Injection™, a generic equivalent of...
Novo Nordisk Secures EMA Approval for Wegovy Delivery Flexibility
Bagsværd, Denmark | April 9, 2026 Novo Nordisk has announced that the European Medicines Agency (EMA) has approved an...
Sun Pharma Launches Semaglutide in India Market
MUMBAI, INDIA, March 21, 2026 Sun Pharmaceutical Industries Limited has announced the launch of its semaglutide injection under the...
Novo Nordisk Wegovy HD Approved with 20% Weight Loss
BAGSVÆRD, Denmark, March 19, 2026 Novo Nordisk A/S announced that the U.S. Food and Drug Administration (FDA) has approved...
Advertisements
China Supreme Court Upholds Novo Nordisk Semaglutide Patent
BAGSVAERD, DENMARK | December 31, 2025 — Novo Nordisk announced that China’s Supreme People’s Court has upheld the validity...
Health Canada Grants Conditional Approval for Wegovy® in MASH
MISSISSAUGA, Ontario — December 15, 2025 — Novo Nordisk Canada Inc. announced that Health Canada has granted conditional marketing...
Emcure Partners with Novo Nordisk to Bring Semaglutide to India
Bengaluru, November 10, 2025 — Global diabetes-care leader Novo Nordisk India has entered into a strategic partnership with Emcure...
Novo Nordisk: Ozempic® Cuts Mortality and CV Events in Real-World Study
Bagsværd, Denmark – September 18, 2025 – Novo Nordisk A/S announced landmark results from the REACH real-world study showing...
Advertisement
